News | October 11, 2024
Privi Speciality Chemicals gets USFDA certificate for camphor product
The company can now expand its business horizon into the area of pharmaceutical applications in the USA
The company can now expand its business horizon into the area of pharmaceutical applications in the USA
Aims to achieve CDMO sales of US$ 400 million by 2028
We now rank 3rd in pharmaceutical production by volume and 14th by value
India’s first trial for a novel autologous BCMA directed CAR-T cell therapy in patients with relapsed / refractory multiple myeloma
DKSH has entered into an exclusive partnership with R-Biomeds to bring the necessary medication to patients in Cambodia
Strategic focus on COCO-model with a nationwide reach of 501 stores
MNI is dedicated to developing and offering phytochemical (plant-based) products and healthcare solutions, aimed at treating metabolic syndrome
Based on ECHO Phase III trial which demonstrated Calquence combination reduced risk of disease progression or death by 27% compared to standard-of-care chemoimmunotherapy
he company will focus on production of any pharmaceutical and biotechnological products
The company plans to advance Ropanicant into double-blind, placebo-controlled Phase-2b clinical study in MDD patients, anticipated to start in early 2025
Subscribe To Our Newsletter & Stay Updated
